Vorasidenib (2) – Voranigo®
Astrocytoma or oligodendroglioma, grade 2, with an IDH1-R132 or IDH2-R172 mutation, following surgical intervention, aged ≥ 12 years and weighing ≥ 40 kg
Characteristics
| Start date | 15.10.2026 |
|---|---|
| Resolution | 15.04.2027 – active procedure |
| INN | Vorasidenib |
| Brand name | Voranigo® |
| Pharm. company | Servier Deutschland GmbH |
| G-BA Procedure ID | D-1387 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Reassessment: Loss of orphan status |
Associated procedures
<< List of all resolutions